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Abstract: Despite the phenomenal success of implants particularly in the realms of dentistry and
orthopaedics, there are still challenges to overcome. The failure of implants resulting from infection,
prosthetic loosening, and non-union continue to be the most notorious examples. The cascade of
fracture healing and bone repair, especially with the presence of an implant, is complex because
it involves a multifaceted immune response alongside the intricate process of bone formation
and remodelling. Bone loss is a serious clinical problem that is frequently accompanied by
chronic inflammation, illustrating that there is a convoluted relationship between inflammation
and bone erosion. The effects of pro-inflammatory factors play a significant role in initiating and
maintaining osteoclastogenesis that results in bone resorption by osteoclasts. This is because there is a
disruption of the relative ratio between Receptor Activator of Nuclear Factor κB-Ligand (RANKL) and
osteoprotegerin (OPG), which is central to modulating bone repair and remodelling. This review aims
to provide a background to the bone remodelling process, the bone repair cascade post-implantation,
and the associated complications. Furthermore, current clinical solutions that can influence bone
formation via either internal or extrinsic mechanisms will be described. These efficacious treatments
for osteolysis via targeting the RANKL/OPG ratio may be crucial to reducing the incidence of related
implant failures in the future.
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1. Introduction—The Clinical Need
Our growing ageing population suffers from chronic age-related diseases such as osteoporosis and
rheumatoid arthritis (RA). Approximately 2% of the world population suffer from RA with chronically
inflamed joints that deteriorates the bone and cartilage until the joint needs to be replaced [1].
Diseases such as RA affects approximately 1.3 million in the U.S. [2] and have increased the prevalence
of total joint replacements. Although there was a report which stated that the incidence of orthopaedic
surgery in patients with RA has been declining over the past two decades; however, in a UK study
of RA patients, large-joint replacement rates remaining constant over time [3]. Hip replacements
were among the most successful surgical procedure developed in the 20th century [4]. However,
a proportion of these prostheses fail and require surgical revision due to aseptic loosening caused by
inflamed peri-prosthetic tissue rich in macrophages, cytokines, and wear particles [4,5]. In dentistry,
the prevailing ailment responsible for bone loss is periodontitis, which can lead to dental implants to
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replace the damaged tooth [1,6]. These orthopaedic implants replace the impaired bone to help restore
normal function to patients, relieve suffering from pain, and subsequently improve their quality of life.
Despite the phenomenal success of implants particularly in the realms of dentistry and orthopaedics,
there are still challenges to overcome. The failure of implants resulting from infection, prosthetic loosening,
and non-union continue to be the most notorious examples [4]. Chronic systemic inflammation, being
one of the hazards of derangement of the homeostatic mechanisms of the musculoskeletal system, can
lead to serious bone loss, which illustrates that there is a convoluted relationship between inflammation
and bone erosion [1]. Significantly elevated levels of Receptor Activator of Nuclear Factor Kappa-B
Ligand (RANKL), Tumour Necrosis Factor-α (TNF-α), and Interleukin-1 (IL-1) are frequently observed
in inflamed tissues adjacent to local osteolysis compared to relevant controls in RA, periodontitis, and
peri-prosthetic tissues [1,4,6,7]. Although these debilitating and painful diseases are distinct from
one another, they share the same key pro-inflammatory mediators, TNF-α and IL-1, that may lead to
excessive bone resorption by the priming of osteoclasts [1,4,6].
2. The Roles of RANK, RANKL, and OPG in Bone Remodelling
The human skeleton consists of more than 200 bones that facilitates movement, protects vital
organs, provides aesthetic features, and supplies a reservoir of blood cells and minerals. These key
functions require a bone structure that, when exposed to different mechanical forces, can subsequently
be remodelled to counteract normal wear and tear throughout life [8]. This remodelling process is
regulated by molecular mechanisms that influence osteoblasts and osteoclasts, which respectively
form new bone and resorb damaged/unneeded bone to achieve a healthy homeostatic balance.
However, when this dynamic equilibrium is disrupted, it results in osteopathic conditions such as
osteoporosis (decreased bone mass), osteopetrosis (increased bone mass), and Paget’s disease (increased
bone remodelling) [8,9]. In the last decade, the discovery of the RANK/RANKL/OPG triad has been
significant in aiding our understanding of the bone remodelling process and consequently the causes of
bone diseases [8,10,11]. The critical role of these three molecules has been demonstrated using transgenic
and gene-knockout studies, but there are aspects of bone biology that remain poorly understood [1,12].
In healthy bone, embedded osteocytes are central in orchestrating normal bone remodelling
by modulating bone-forming osteoblasts and bone-resorbing osteoclasts through cell signalling
molecules, most prolifically through RANKL (Figure 1) [13]. It is known that microfractures frequently
occur with approximately 1–2 million sites in the adult skeleton that initiate the bone remodelling
process in what is called a bone remodelling unit [8]. Osteocytes (mature osteoblasts embedded
in bone matrix) are stellar-shaped with long processes that detect these microfractures and undergo
apoptosis, which stops the release of sclerostin (osteogenesis inhibitor) [14–16]. Neighbouring osteocytes
sense this and release biomolecular signals, including growth factors and cytokines that attract
bone marrow-derived mesenchymal stem or stromal cells (MSCs). These MSCs proliferate and
differentiate into pre-osteoblasts that secrete Macrophage Colony-Stimulating Factor (M-CSF) and
express RANKL [17]. These stimulate colony-forming unit–macrophages (CFU-M, macrophage
pre-cursors) to differentiate into pre-osteoclasts, which fuse into multinucleated osteoclasts that display
RANK receptors. Therefore, inflammation is the initial phase needed in bone remodelling, as well as
bone healing.
Osteoclasts become activated when bound to RANKL either indirectly, in its soluble form or
directly, to membrane-bound RANKL on the pre-osteoblasts [10,17]. Then, bone-lining cells expose the
bone matrix surface to the osteoclasts that seal a zone where they secrete acid (e.g., hydrochloric acid)
and hydrolytic enzymes (e.g., cathepsin K), which resorbs the damaged bone [8]. This simultaneously
releases fragments of growth factors from the matrix including Transforming Growth Factor-β (TGF-β)
and Bone Morphogenetic Proteins (BMPs), which stimulates the differentiation of MSCs into mature
osteoblasts [16,18]. Then, the osteoblasts line the resorbed cavity and fill it with osteoid which
forms woven bone. Synchronously, osteoblasts secrete osteoprotegerin (OPG) that acts as a decoy
receptor, antagonistically binds to RANKL which reduces osteoclastogenesis and drives apoptosis
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of the pre-existing osteoclasts [12,18]. Finally, the woven bone is mineralised over a few months by
the osteoblasts, which eventually undergo apoptosis, or become embedded and differentiate into
osteocytes, or differentiate further into bone-lining cells [18].
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molecules that can be divided into three main groups: pro-inflammatory cytokines, growth factors
including the TGF-β superfamily members, and angiogenic factors [24].
Inflammation is the primary phase that initiates normal bone turnover. Post-implantation, there is
an immediate acute inflammatory response for the first three days. A haematoma is formed containing
platelets and inflammatory cells that release Platelet-Derived Growth Factor (PDGF), TGF-β, and
pro-inflammatory cytokines, including TNF-α, IL-1, and IL-6, that recruit other inflammatory cells
and MSCs [23]. These pro-inflammatory cytokines increase expression in T-cells and osteoblasts
for RANKL and M-CSF, whilst OPG expression is reduced, in order to cultivate osteoclasts to
resorb necrotic tissue [6,21,25]. Migrated MSCs are stimulated by the TGF-β superfamily members,
growth differentiation factors (GDFs), and BMPs to proliferate and differentiate into osteogenic and
chondrogenic lineages, respectively, to begin intramembranous and endochondral (via cartilage)
ossification [26]. During the cartilage formation phase, OPG expression in chondrocytes peaks,
leading to an increase in bone mass through the negative regulation of osteoclast formation; then
the OPG expression decreases as calcified cartilage is substituted by woven bone [25,27]. RANKL,
M-CSF, and TNF-α are considered to aid migration of bone cells to start cartilage mineralisation [26].
After about 14 days, these cells cease to proliferate and express Vascular Endothelial Growth Factor
(VEGF) to encourage neoangiogenesis by endothelial MSCs to form vascularised woven bone [23,26].
Subsequently, there is another rise in IL-1, IL-6, and TNF-α respectively, which upregulates RANKL
in osteoblasts and drives osteoclastogenesis [10,24]. In particular, IL-β1 can stimulate pre-osteoclasts
directly to fuse into multinucleated osteoclasts and can inhibit apoptosis to prolong their lifespan [28].
Therefore, osteoclasts can resorb the woven bone, which is then remodelled into lamellar cortical bone
and trabecular bone by osteoblasts as previously described.
4. Post-Implantation Complications
The local damage caused by implantation and the presence of a foreign material elicits an immune
response that uses chemokines to attract circulating monocytes to the area, which differentiate into
activated macrophages that release TNF-α, IL-1, IL-6, and M-CSF [28,29]. In chronic inflammation,
these macrophages exist in abundance and have been found to differentiate further into pre-osteoclasts
and then into mature osteoclasts in the presence of M-CSF [1]. Furthermore, these macrophages can
express RANK, RANKL, and M-CSF, which enables self-activated osteoclastogenesis. The process is
accelerated when macrophages ingest prosthetic wear particles [4,29–33]. The use of bone cements
to fix implants has also been shown to increase RANKL production and therefore the RANKL/OPG
ratio [34,35]. In addition, T-cells contribute to the release of RANKL, M-CSF, TNF-α, and IL-1,
which can trigger pre-osteoblasts and MSCs to also express RANKL, thus further increasing the
RANKL/OPG ratio [21,29,36,37]. Moreover, prostaglandin-E2 and 1,25(OH)2D3 (active metabolite of
vitamin D) were often observed in peri-prosthetic tissue and found to contribute to increasing the
RANKL/OPG ratio [38]. Other researchers have demonstrated that TNF-α and IL-1 can induce
osteoclastogenesis alone in the absence of RANKL [28,39]. Finally, the accompaniment of IL-6
expression from inflammatory cells has been correlated with osteoclast formation and peri-prosthetic
infection [40,41]. In summary, surrounding the implant there is a large host of macrophages that in
the presence of M-CSF, can differentiate to create a large pool of active osteoclasts via two pathways:
by binding to RANKL secreted from the various cells aforementioned; or by direct stimulation from
TNF-α and IL-1.
It is worth noting that macrophages isolated from peri-prosthetic tissue have been found to
differentiate into mature osteoclasts without the company of MSCs or osteoblastic cells, and contained
higher levels of RANKL mRNA compared to OPG mRNA [29]. In fact, most of the RANKL is produced
by leucocytes, which negates the need for osteoblastic cells or MSCs for support [1]. A number of
studies have noted high RANKL/OPG ratios compared to controls, and the level of severity was
correlated with higher ratios across different bone loss pathologies [6,28,42]. These results indicate that
there is markedly more RANKL readily available to bind with RANK than there is OPG to counteract
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its effect, so the activity of OPG is dampened. Furthermore, there is the natural generation of bone
resorption exerted by mechanical stimulation and fluid pressure which is significantly enhanced when
exposed to osteolytic cytokines that assists the progression of aseptic loosening [43–45]. All of these
findings demonstrate this dire situation illustrated in Figure 2, that chronic inflammation rapidly
cascades into severe osteolysis which inevitably requires clinical intervention [1,11,21,28].
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to unify the material with the surrounding bone) [48,49]. Implants have also been designed with pores
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tissue ingrowth and angiogenesis in or er to prevent osteolysis developing post-implantatio .
A number of studies have shown that therapeutic interventions can be designed to address the
bone remodelling by altering the RANKL/OPG ratio. This ca be done through solutions that aim
to promote bone formation either: (1) by internally correcting the balance f intrinsic RANKL/OPG
expression, r (2) by intr ducing exogenous molecules t manipulate and e hance the RANKL/OPG ratio.
5.1. Correcting the Intrinsic RANKL/OPG Balance Internally
For efficacious bone repair, the site must have an adequate blood supply and withstand a steady
increase in biomechanical stability, and the implant should integrate into the native bone tissue [26].
Research has established that complications arise from metal implant corrosion in the body, leading to
the release of metal ions that cause an inflammatory and immune response [50]. Implants are typically
made from titanium or stainless steel. It is now known that osteoclasts can directly corrode titanium
and stainless steel surfaces and then release ions, which induces the secretion of pro-inflammatory
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cytokines and RANKL, resulting in osteoclastogenesis and subsequent adjacent osteolysis and aseptic
loosening [51–53]. Therefore, the choice of material may be crucial to altering RANKL/OPG ratios
since studies conducted on failed implants have revealed differences in osteoclast formation depending
on the material chemistry [29]. For instance, biosilica may be a possible prophylactic material that can
upregulate OPG synthesis to support bone formation by decreasing the RANKL/OPG ratio [54,55].
Furthermore, microstructured titanium surfaces have been shown to enhance osseointegration by
increasing OPG expression in bone remodelling [56]. Titanium nitride oxide coating on rough titanium
surfaces has also been shown to stimulate the proliferation of human primary osteoblasts [57].
5.2. Enhancing the RANKL/OPG Ratio Extrinsically
Anti-inflammatory drugs obstruct chronic inflammation from developing by inhibiting the
pro-inflammatory cytokines. For example, oral pentoxifylline has been successful in reducing TNF-α
release from macrophages exposed to prosthetic particle debris [58]. This reduces osteoclast activity
that is stimulated through TNF-α. However, anti-inflammatory drugs are only partially effective
because they do not block the expression of RANKL, unlike OPG that can antagonise RANKL [21].
A multifaceted approach that targets TNF-α, IL-1, and RANKL may be more efficacious [1]. Today’s
most popular anti-resorptive pharmaceutical are bisphosphonates that treat osteolytic conditions
including Paget’s disease, osteoporosis, and bone metastases, by inhibiting osteoclast formation and
promoting osteoblast maturation [59–61]. Bisphosphonates act by binding to bone minerals that are
ingested by osteoclasts and disrupt their resorptive ability [60]. Although it has been debated whether
this action can be sustained over long-term treatment, which has been associated with increased
osteoclast populations [60].
On the other hand, OPG and OPG-like molecules are promising candidates to block RANK/RANKL
activation and inhibit osteoclastogenesis in order to prevent or delay osteolysis and subsequent prosthetic
failure [29]. It is clear that OPG is essential for maintaining a healthy bone metabolism by diminishing
bone resorption and increasing the density, area, and strength of bone [11,62]. Genetic deletion of OPG
in mice results in severe early onset osteoporosis and a high fracture incidence [9,10]. Therefore, it is
unsurprising that therapeutic administration of OPG is successful in treating osteolytic conditions by
supressing bone resorption [9,11,63].
The hallmarks of OPG have led to the development of denosumab, a fully human monoclonal
antibody to RANKL that behaves like OPG by binding to RANKL and preventing subsequent
osteoclastogenesis, but with the additional advantage of having a significantly longer half-life and
therefore requiring less frequent administration [11,60]. Furthermore, current clinical results have
demonstrated that denosumab is more efficacious than bisphosphonate treatments by rapidly reducing
bone resorption to a greater extent, increasing overall bone mineral density, and significantly reducing
fracture incidence [60,64]. This may be because denosumab inhibits RANKL, which is readily
available in the extracellular space, and therefore is not limited like the bisphosphonates that rely
on being endocytosed by osteoclasts to yield their actions internally [60]. Denosumab has been
clinically successful in treating osteoporosis, rheumatoid arthritis, and bone metastases [65]. Therefore,
denosumab could be modified in the future and used to treat other osteolytic pathologies, including
excessive bone resorption post-implantation.
Conversely, bisphosphonates, denosumab, and any therapeutic that alters the RANKL/OPG ratio
must be used with caution and closely monitored since a lack of normal, healthy bone remodelling
can lead to other problems such as osteonecrosis of the jaw [66–68]. Bisphosphonates carry undesired
side effects due to its non-specificity. In contrast, although the denosumab antibody is highly specific,
it can travel to impact bone anywhere in the body [60]. Therefore, a conducive research effort should
be made to adapt implants to include a limited local delivery of anti-RANKL therapeutics that would
reduce chronic inflammation of the wound site, but concurrently allow acute inflammation that
initiates the cascade for normal bone healing and remodelling to reduce the need for revision surgery.
Aforementioned, to date this has been mainly achieved through altering intrinsic RANKL/OPG ratio
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internally by using implant surface topography and chemistry to influence cell behaviour to promote
bone healing and reduce chronic inflammation.
6. Conclusions
Over the last decade, increased understanding of the complex aetiology of diseases related to
bone metabolism has inspired the development of innovative, efficacious treatments for osteolysis that
target the RANKL-L/OPG ratio to reduce the incidence of related implant failures. While mechanical
properties of biomaterials remain important, it is recommended that future implant designs should
give an even greater consideration to local cellular responses. Adoption of this more holistic approach
has the potential to increase the rate of bone tissue regeneration, providing enhanced osseointegration
and improved long-term clinical success.
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